Abstract P6-06-32: 4EVER: Does mTOR inhibition have a major clinical impact on bone health in postmenopausal women with hormone receptor positive (HR+) locally advanced breast cancer treated with everolimus (EVE) in combination with exemestane (EXE)?

Mapping Intimacies ◽

10.1158/0008-5472.sabcs13-p6-06-32 ◽

2013 ◽

Author(s):

P Hadji ◽

H Tesch ◽

PA Fasching ◽

DI Lueftner ◽

W Janni ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Bone Health ◽

Hormone Receptor ◽

Locally Advanced Breast Cancer ◽

Locally Advanced ◽

Clinical Impact ◽

Mtor Inhibition ◽

Hormone Receptor Positive

Download Full-text

Abstract P3-06-04: 4EVER: The impact of mTOR inhibition on bone health in postmenopausal women with hormone receptor positive (HR+) advanced breast cancer treated with everolimus (EVE) in combination with exemestane (EXE)

10.1158/1538-7445.sabcs14-p3-06-04 ◽

2015 ◽

Author(s):

Peyman Hadji ◽

Hans Tesch ◽

Oliver Stoetzer ◽

Thomas Decker ◽

Christian M Kurbacher ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Bone Health ◽

Hormone Receptor ◽

Advanced Breast ◽

Mtor Inhibition ◽

Hormone Receptor Positive ◽

The Impact

Download Full-text

A randomized, phase III trial exploring the effects of neoadjuvant sequential treatment with steroidal (exemestane) and nonsteroidal (anastrozole) aromatase inhibitors on biomarkers in postmenopausal women with hormone receptor-positive locally advanced breast cancer

Breast Cancer Research ◽

10.1186/bcr2316 ◽

2009 ◽

Vol 11 (S1) ◽

Author(s):

OC Freedman ◽

E Amir ◽

G Dranitsaris ◽

M Dowsett ◽

DEC Cole ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Aromatase Inhibitors ◽

Hormone Receptor ◽

Locally Advanced Breast Cancer ◽

Locally Advanced ◽

Phase Iii ◽

Phase Iii Trial ◽

Hormone Receptor Positive

Download Full-text

The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial

Journal of Bone Oncology ◽

10.1016/j.jbo.2018.09.010 ◽

2019 ◽

Vol 14 ◽

pp. 100199 ◽

Cited By ~ 1

Author(s):

Peyman Hadji ◽

Oliver Stoetzer ◽

Thomas Decker ◽

Christian M. Kurbacher ◽

Frederik Marmé ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Bone Health ◽

Hormone Receptor ◽

Mammalian Target Of Rapamycin ◽

Advanced Breast ◽

Hormone Receptor Positive ◽

Phase Iiib ◽

The Impact

Download Full-text

Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30688-5 ◽

2018 ◽

Vol 19 (1) ◽

pp. 87-100 ◽

Cited By ~ 151

Author(s):

Angelo Di Leo ◽

Stephen Johnston ◽

Keun Seok Lee ◽

Eva Ciruelos ◽

Per E Lønning ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Advanced Breast ◽

Phase 3 ◽

Double Blind ◽

Mtor Inhibition ◽

Double Blind Placebo ◽

Hormone Receptor Positive

Download Full-text

breast cancer, locally advanced and metastatic First-line ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC)

Annals of Oncology ◽

10.1093/annonc/mdw435.03 ◽

2016 ◽

Vol 27 ◽

pp. vi553 ◽

Cited By ~ 3

Author(s):

G.N. Hortobagyi ◽

S.M. Stemmer ◽

H.A. Burris ◽

Y.S. Yap ◽

G.S. Sonke ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Locally Advanced ◽

Advanced Breast ◽

First Line ◽

Hormone Receptor Positive

Download Full-text

Faculty Opinions recommendation of Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.732279400.793559076 ◽

2019 ◽

Author(s):

Ahmad Awada

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Advanced Breast ◽

Phase 3 ◽

Double Blind ◽

Mtor Inhibition ◽

Double Blind Placebo ◽

Hormone Receptor Positive

Download Full-text

Ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative advanced breast cancer (ABC) who received no prior therapy for advanced disease

Geburtshilfe und Frauenheilkunde ◽

10.1055/s-0036-1592812 ◽

2016 ◽

Vol 76 (10) ◽

Author(s):

EM Grischke ◽

A Nusch ◽

N Marschner ◽

W Abenhardt ◽

J Wilke ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Advanced Disease ◽

Advanced Breast ◽

Prior Therapy ◽

Hormone Receptor Positive

Download Full-text

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2

Annals of Oncology ◽

10.1093/annonc/mdu009 ◽

2014 ◽

Vol 25 (4) ◽

pp. 808-815 ◽

Cited By ~ 87

Author(s):

H.S. Rugo ◽

K.I. Pritchard ◽

M. Gnant ◽

S. Noguchi ◽

M. Piccart ◽

...

Keyword(s):

Breast Cancer ◽

Adverse Events ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Time Course ◽

Advanced Breast ◽

Hormone Receptor Positive

Download Full-text

Incidence of pathologic complete response in women treated with preoperative chemotherapy for locally advanced breast cancer: correlation of histology, hormone receptor status, Her2/Neu, and gross pathologic findings

Annals of Diagnostic Pathology ◽

10.1016/j.anndiagpath.2009.02.003 ◽

2009 ◽

Vol 13 (3) ◽

pp. 151-157 ◽

Cited By ~ 25

Author(s):

Isabel Alvarado-Cabrero ◽

Georgia Alderete-Vázquez ◽

Marissa Quintal-Ramírez ◽

Marcia Patiño ◽

Erika Ruíz

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Preoperative Chemotherapy ◽

Hormone Receptor ◽

Locally Advanced Breast Cancer ◽

Locally Advanced ◽

Pathologic Complete Response ◽

Complete Response ◽

Hormone Receptor Status ◽

Pathologic Findings

Download Full-text

Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer for whom letrozole therapy is deemed appropriate: An expanded access study in Australia and India

Asia-Pacific Journal of Clinical Oncology ◽

10.1111/ajco.13653 ◽

2021 ◽

Author(s):

Sherene Loi ◽

Christos S. Karapetis ◽

Nicole McCarthy ◽

Catherine Oakman ◽

Andrew Redfern ◽

...

Keyword(s):

Breast Cancer ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Growth Factor Receptor ◽

Hormone Receptor Positive ◽

Epidermal Growth

Download Full-text